- Home
- GSIW vs PPBT Comparison
GSIW vs PPBT Comparison
Compare GSIW & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- PPBT
- Stock Information
- Founded
- GSIW 2016
- PPBT 2010
- Country
- GSIW Hong Kong
- PPBT Israel
- Employees
- GSIW N/A
- PPBT N/A
- Industry
- GSIW
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- PPBT Health Care
- Exchange
- GSIW Nasdaq
- PPBT Nasdaq
- Market Cap
- GSIW 27.2M
- PPBT 6.3M
- IPO Year
- GSIW 2023
- PPBT N/A
- Fundamental
- Price
- GSIW $1.56
- PPBT $2.49
- Analyst Decision
- GSIW
- PPBT Strong Buy
- Analyst Count
- GSIW 0
- PPBT 1
- Target Price
- GSIW N/A
- PPBT $33.00
- AVG Volume (30 Days)
- GSIW 1.9M
- PPBT 22.4K
- Earning Date
- GSIW 01-01-0001
- PPBT 08-15-2025
- Dividend Yield
- GSIW N/A
- PPBT N/A
- EPS Growth
- GSIW N/A
- PPBT N/A
- EPS
- GSIW N/A
- PPBT N/A
- Revenue
- GSIW $1,313,795.00
- PPBT N/A
- Revenue This Year
- GSIW N/A
- PPBT N/A
- Revenue Next Year
- GSIW N/A
- PPBT N/A
- P/E Ratio
- GSIW N/A
- PPBT N/A
- Revenue Growth
- GSIW N/A
- PPBT N/A
- 52 Week Low
- GSIW $0.35
- PPBT $2.00
- 52 Week High
- GSIW $12.30
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- GSIW 72.24
- PPBT 52.01
- Support Level
- GSIW $1.43
- PPBT $2.26
- Resistance Level
- GSIW $1.62
- PPBT $2.50
- Average True Range (ATR)
- GSIW 0.14
- PPBT 0.13
- MACD
- GSIW -0.02
- PPBT 0.00
- Stochastic Oscillator
- GSIW 47.62
- PPBT 58.82
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.